Get the Stockscreener App
0.7302
44.68%
-0.5898
After Hours:
.68
-0.0502
-6.87%
Intensity Therapeutics Inc stock is traded at $0.7302, with a volume of 194.65M.
It is down -44.68% in the last 24 hours and up +200.87% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$1.32
Open:
$0.9856
24h Volume:
194.65M
Relative Volume:
6.89
Market Cap:
$35.82M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.6181
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+206.94%
1M Performance:
+200.87%
6M Performance:
+24.16%
1Y Performance:
-77.53%
1-Day Range:
$0.70
$1.15
1-Week Range:
$0.23
$1.74
52-Week Range:
$0.1853
$3.40
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.7302 | 64.75M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Intensity Therapeutics Inc Stock (INTS) Latest News
How interest rate cuts could boost Intensity Therapeutics Inc. stockJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Using Bollinger Bands to evaluate Intensity Therapeutics Inc.Quarterly Performance Summary & Weekly High Return Stock Opportunities - newser.com
How to track smart money flows in Intensity Therapeutics Inc.2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com
Does Intensity Therapeutics Inc. show high probability of rebound2025 Key Highlights & Precise Buy Zone Tips - newser.com
Ranking Intensity Therapeutics Inc. among high performing stocks via tools2025 Earnings Surprises & High Return Stock Watch Alerts - newser.com
How Intensity Therapeutics Inc. stock performs in stagflationJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
How Intensity Therapeutics Inc. stock trades before earnings2025 Breakouts & Breakdowns & AI Powered Market Entry Strategies - newser.com
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset - MSN
Intensity Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Intensity Therapeutics Enters Securities Purchase Agreement - TipRanks
INTS to raise $4.0M via 5,000,000-share registered direct sale - Stock Titan
Intensity Therapeutics prices $4 million registered direct offering By Investing.com - Investing.com South Africa
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics Prices $4 Million Direct Offering - MarketScreener
Intensity Therapeutics prices 5M shares at 80c in registered direct offering - TipRanks
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics, Inc. (INTS) stock tumbles 30% as $4M direct offering sparks investor concern - parameter.io
Unexpected Surge: Analyzing INTS Performance - timothysykes.com
Intensity Therapeutics prices $4 million registered direct offering - Investing.com
INTS Stock Price and Chart — NASDAQ:INTS - TradingView
Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News - ts2.tech
Intensity Therapeutics stock tumbles after pricing $4 million offering By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock tumbles after pricing $4 million offering - Investing.com
Intensity Therapeutics stock up nearly 400% on solid tumour data - Yahoo Finance
Intensity Therapeutics (Nasdaq: INTS) prices $4M registered direct, selling 5M shares - Stock Titan
Is Intensity Therapeutics Inc. stock oversold or undervaluedJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why Intensity Therapeutics Inc. stock is favored by top institutionsWeekly Market Report & AI Optimized Trade Strategies - newser.com
Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics - Yahoo! Finance UK
Volume spikes in Intensity Therapeutics Inc. stock – what they meanMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
How to integrate Intensity Therapeutics Inc. into portfolio analysis toolsEarnings Miss & Verified Trade Idea Suggestions - newser.com
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know - inkl
US Stock Market top gainers and losers on October 30: Intensity Therapeutics, Inc. sees nearly 400% jump, - The Economic Times
Positive Phase 1/2 clinical data for cancer candidate drug propels Intensity Therapeutics (INTS.US) stock up by 395%. - 富途牛牛
Why Is Retail Going Gaga Over INTS Stocks Today? - Stocktwits
Intensity Therapeutics Shares Soar on Promising Cancer Trial Results - El-Balad.com
Intensity Therapeutics publishes cancer treatment study results in Lancet journal By Investing.com - Investing.com South Africa
Intensity Therapeutics shares skyrocket after strong cancer drug trial results - Business Upturn
Intensity Therapeutics shares more than double on promising cancer trial data - TradingView
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):